|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rustgi AK and El-Serag HB: Esophageal
carcinoma. N Engl J Med. 371:2499–2509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen DJ and Leichman L: Controversies in
the treatment of local and locally advanced gastric and esophageal
cancers. J Clin Oncol. 33:1754–1759. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gray TA, Alsamman K, Murray E, Sims AH and
Hupp TR: Engineering a synthetic cell panel to identify signalling
components reprogrammed by the cell growth regulator anterior
gradient-2. Mol Biosyst. 10:1409–1425. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park SW, Zhen G, Verhaeghe C, Nakagami Y,
Nguyenvu LT, Barczak AJ, Killeen N and Erle DJ: The protein
disulfide isomerase AGR2 is essential for production of intestinal
mucus. Proc Natl Acad Sci USA. 106:6950–6955. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brychtova V, Vojtesek B and Hrstka R:
Anterior gradient 2: A novel player in tumor cell biology. Cancer
Lett. 304:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thompson DA and Weigel RJ: hAG-2, the
Human Homologue of the Xenopus laevis Cement Gland Gene XAG-2, is
coexpressed with estrogen receptor in breast cancer cell lines.
Biochem Biophys Res Commun. 251:111–116. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alavi M, Mah V, Maresh EL, Bagryanova L,
Horvath S, Chia D, Goodglick L and Liu AY: High expression of AGR2
in lung cancer is predictive of poor survival. BMC Cancer.
15:6552015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Armes JE, Davies CM, Wallace S, Taheri T,
Perrin LC and Autelitano DJ: AGR2 expression in ovarian tumours: A
potential biomarker for endometrioid and mucinous differentiation.
Pathology. 45:49–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lowe AW, Olsen M, Hao Y, Lee SP, Taek Lee
K, Chen X, Van de Rijn M and Brown PO: Gene expression patterns in
pancreatic tumors, cells and tissues. PLoS One. 2:e3232007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Forootan SS, Liu D, Barraclough
R, Foster CS, Rudland PS and Ke Y: Increased expression of anterior
gradient-2 is significantly associated with poor survival of
prostate cancer patients. Prostate Cancer Prostatic Dis.
10:293–300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tian SB, Tao KX, Hu J, Liu ZB, Ding XL,
Chu YN, Cui JY, Shuai XM, Gao JB, Cai KL, et al: The prognostic
value of AGR2 expression in solid tumours: A systematic review and
meta-analysis. Sci Rep. 7:155002017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma SR, Wang WM, Huang CF, Zhang WF and Sun
ZJ: Anterior gradient protein 2 expression in high grade head and
neck squamous cell carcinoma correlated with cancer stem cell and
epithelial mesenchymal transition. Oncotarget. 6:8807–8821. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun B, Cheng Z and Sun J: Associations of
MACC1, AGR2, and KAI1 expression with the metastasis and prognosis
in head and neck squamous cell carcinoma. Int J Clin Exp Patho.
11:822–830. 2018.PubMed/NCBI
|
|
15
|
Sweeny L, Liu Z, Bush BD, Hartman Y, Zhou
T and Rosenthal EL: CD147 and AGR2 expression promote cellular
proliferation and metastasis of head and neck squamous cell
carcinoma. Exp Cell Res. 318:1788–1798. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma SR, Mao L, Deng WW, Li YC, Bu LL, Yu
GT, Zhang WF and Sun ZJ: AGR2 promotes the proliferation, migration
and regulates epithelial-mesenchymal transition in salivary adenoid
cystic carcinoma. Am J Transl Res. 9:507–519. 2017.PubMed/NCBI
|
|
17
|
Wang Z, Hao Y and Lowe AW: The
Adenocarcinoma-associated antigen, AGR2, promotes tumor growth,
cell migration, and cellular transformation. Cancer Res.
68:492–497. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hrstka R, Bouchalova P, Michalova E,
Matoulkova E, Muller P, Coates PJ and Vojtesek B: AGR2 oncoprotein
inhibits p38 MAPK and p53 activation through a DUSP10-mediated
regulatory pathway. Mol Oncol. 10:652–662. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pohler E, Craig AL, Cotton J, Lawrie L,
Dillon JF, Ross P, Kernohan N and Hupp TR: The Barrett's antigen
anterior gradient-2 silences the p53 transcriptional response to
DNA damage. Mol Cell Proteomics. 3:534–547. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Siliciano JD, Canman CE, Taya Y, Sakaguchi
K, Appella E and Kastan MB: DNA damage induces phosphorylation of
the amino terminus of p53. Genes Dev. 11:3471–3481. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Joruiz SM and Bourdon JC: p53 Isoforms:
Key regulators of the cell fate decision. Cold Spring Harb Perspect
Med. 6:a0260392016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lane DP: Cancer. p53, guardian of the
genome. Nature. 358:15–16. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Albrechtsen N, Dornreiter I, Grosse F, Kim
E, Wiesmüller L and Deppert W: Maintenance of genomic integrity by
p53: Complementary roles for activated and non-activated p53.
Oncogene. 18:7706–7717. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM classification of malignant tumours. John Wiley
& Sons; 2016
|
|
26
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wagata T, Shibagaki I, Imamura M, Shimada
Y, Toguchida J, Yandell DW, Ikenaga M, Tobe T and Ishizaki K: Loss
of 17p, mutation of the p53 gene, and overexpression of p53 protein
in esophageal squamous cell carcinomas. Cancer Res. 53:846–850.
1993.PubMed/NCBI
|
|
28
|
Saeki H, Kitao H, Yoshinaga K, Nakanoko T,
Kubo N, Kakeji Y, Morita M and Maehara Y: Copy-neutral loss of
heterozygosity at the p53 locus in carcinogenesis of esophageal
squamous cell carcinomas associated with p53 mutations. Clin Cancer
Res. 17:1731–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Janssens V, Van Hoof C, De Baere I,
Merlevede W and Goris J: The phosphotyrosyl phosphatase activator
gene is a novel p53 target gene. J Biol Chem. 275:20488–20495.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsuji T, Satoyoshi R, Aiba N, Kubo T,
Yanagihara K, Maeda D, Goto A, Ishikawa K, Yashiro M and Tanaka M:
Agr2 mediates paracrine effects on stromal fibroblasts that promote
invasion by gastric signet-ring carcinoma cells. Cancer Res.
75:356–366. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu Z, Gu Y, Han B, Zhang J, Li Z, Tian K,
Young CY and Yuan H: Knockdown of AGR2 induces cellular senescence
in prostate cancer cells. Carcinogenesis. 33:1178–1186. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu QG, Li YJ and Yao L: Knockdown of AGR2
induces cell apoptosis and reduces chemotherapy resistance of
pancreatic cancer cells with the involvement of ERK/AKT axis.
Pancreatology. 18:678–688. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu R, Qian M, Zhou T and Cui P: TP53
mediated miR-3647-5p prevents progression of cervical carcinoma by
targeting AGR2. Cancer Med. 8:6095–6105. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pizzi M, Fassan M, Balistreri M,
Galligioni A, Rea F and Rugge M: Anterior gradient 2 overexpression
in lung adenocarcinoma. Appl Immunohistochem Mol Morphol. 20:31–36.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
DiMaio MA, Kwok S, Montgomery KD, Lowe AW
and Pai RK: Immunohistochemical panel for distinguishing esophageal
adenocarcinoma from squamous cell carcinoma: A combination of p63,
cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows
optimal subtyping. Hum Pathol. 43:1799–1807. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sicari D, Centonze FG, Pineau R, Le Reste
PJ, Negroni L, Chat S, Mohtar MA, Thomas D, Gillet R, Hupp T, et
al: Reflux of endoplasmic reticulum proteins to the cytosol
inactivates tumor suppressors. EMBO Rep. 22:e514122021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Soussi T and Lozano G: p53 mutation
heterogeneity in cancer. Biochem Biophys Res Commun. 331:834–842.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Barnas C, Martel-Planche G, Furukawa Y,
Hollstein M, Montesano R and Hainaut P: Inactivation of the p53
protein in cell lines derived from human esophageal cancers. Int J
Cancer. 71:79–87. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bennett WP, Hollstein MC, He A, Zhu SM,
Resau JH, Trump BF, Metcalf RA, Welsh JA, Midgley C, Lane DP, et
al: Archival analysis of p53 genetic and protein alterations in
Chinese esophageal cancer. Oncogene. 6:1779–1784. 1991.PubMed/NCBI
|
|
40
|
Finlay CA, Hinds PW, Tan TH, Eliyahu D,
Oren M and Levine AJ: Activating mutations for transformation by
p53 produce a gene product that forms an hsc70-p53 complex with an
altered half-life. Mol Cell Biol. 8:531–539. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hrstka R, Murray E, Brychtova V, Fabian P,
Hupp TR and Vojtesek B: Identification of an AKT-dependent
signalling pathway that mediates tamoxifen-dependent induction of
the pro-metastatic protein anterior gradient-2. Cancer Lett.
333:187–193. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ondrouskova E, Sommerova L, Nenutil R,
Coufal O, Bouchal P, Vojtesek B and Hrstka R: AGR2 associates with
HER2 expression predicting poor outcome in subset of estrogen
receptor negative breast cancer patients. Exp Mol Pathol.
102:280–283. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Arumugam T, Deng D, Bover L, Wang H,
Logsdon CD and Ramachandran V: New blocking antibodies against
novel AGR2-C4.4A pathway reduce growth and metastasis of pancreatic
tumors and increase survival in mice. Mol Cancer Ther. 14:941–951.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li LY, Tang JT, Jia LQ and Li PW:
Mutations of p53 gene exons 4–8 in human esophageal cancer. World J
Gastroenterol. 11:2998–3001. 2005. View Article : Google Scholar : PubMed/NCBI
|
